Evidence map›Paper›PMID 39881845›Full record

ArticleFrontiers in medicine2025

Upregulation of HSP90α in the lungs and circulation in sarcoidosis.

Takuma Isshiki, Motoko Sunakawa, Megan Vierhout, Anmar Ayoub, Pareesa Ali, Safaa Naiel, Shion Miyoshi, Asghar Naqvi, Nathan Hambly, Kazuma Kishi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Takuma IsshikiDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
Motoko SunakawaDepartment of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan.
Megan VierhoutDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
Anmar AyoubDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
Pareesa AliDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
Safaa NaielDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
Shion MiyoshiDepartment of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan.
Asghar NaqviDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
Nathan HamblyDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
Kazuma KishiDepartment of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan.
Kjetil AskDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
Martin R J KolbDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sarcoidosis is a systemic granulomatous disease of unknown cause. Natural improvement with favorable outcome is common, but a significant number of patients present with difficult to manage and progressive disease. The identification of biomarkers associated with disease activity and progression is warranted. Extracellular heat shock protein 90 (HSP90) Materials and methods: HSP90α protein expression in lung tissues derived from patients diagnosed with sarcoidosis and control subjects was assessed by immunohistochemistry. Serum HSP90α concentration was measured in sarcoidosis patients and healthy controls and correlated with clinical outcomes. Bronchoalveolar lavage fluid (BALF) was collected and analyzed for HSP90α expression. Extracellular HSP90α released from macrophages was examined in human primary cells and an immortalized cell line. Results: Macrophages and granulomas in sarcoidosis-affected lungs showed high HSP90α expression. Serum HSP90α levels were elevated in sarcoidosis patients compared with controls and correlated with BALF HSP90α levels. HSP90α concentrations in the circulation were correlated with biomarkers of disease stage. Both primary and immortalized macrophages showed a high capacity for secreting extracellular HSP90α. Conclusion: These results demonstrate that macrophages in the lungs of sarcoidosis patients produce high levels of HSP90α, suggesting HSP90α as a potential biomarker and therapeutic target.

Indexed as

biomarkerextracellular Hsp90αgranulomaHsp90αsarcoidosis

Identifiers

PMID39881845
PMCPMC11774731

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.